aneb-001
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2021 (NCT05282797)
Timeline
Indications
Mechanism of action
- Caspase-8ANTAGONIST
CASP8 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)NC(=O)N1CC(O[C@H](c2ccc(Cl)cc2)c2ccccc2C(F)(F)F)C1- Mol. weight
- 440.89 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095165 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211607 | Phase 1 | Sep 22, 2025 | Anebulo Pharmaceuticals, National Institute on Drug Abuse (NIDA) |
| NCT05282797 | Phase 2 | Dec 15, 2021 | Anebulo Pharmaceuticals, Leiden University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anebulo Pharmaceuticals | For profit | 2 | 2 | 2 | 2021 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1